

## Novel Compound Heterozygous Mutations in *RAG1* in a Patient with Cutaneous Lymphoproliferative Disease

Cong-cong XU<sup>#</sup>, Zhi-ming CHEN<sup>#</sup>, Jing-shu XIONG, Lu GAN, Ying ZHANG, Hao CHEN\* and Jian-fang SUN  
 Department of Pathology, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China. \*E-mail: ch76ch@163.com

<sup>#</sup>These authors contributed equally to this work.

Accepted Sep 18, 2018; Epub ahead of print Sep 18, 2018

Severe combined immunodeficiency (SCID) is characterized by absent or non-functional T and B cells. A series of different genetic variants are known to cause SCID. Mutations in recombinase activating genes 1 and 2 (*RAG1* and *RAG2*) are the most common mutations of T-B-NK+ SCID (1). During the development of T and B cells, these genes are responsible for the rearrangements of the variable, diversity and joining segments of T- and B-cell receptors (2). The first case of SCID caused by mutation in *RAG1* was reported in 1996 by Schwarz et al. (3). Mutations at *RAG1* located within human 11p13 chromosome result in many kinds of primary immunodeficiency diseases, including SCID, Omenn syndrome (OS) and selective immunoglobulin A deficiency (SIgAD) (4). We described here a patient who was diagnosed with SCID with cutaneous lymphoproliferative diseases caused by novel mutations in *RAG1*.

### CASE REPORT

A 5-year-old boy was referred to our clinic with a 3-year history of asymptomatic infiltrated erythematous plaques on his trunk and limbs. He was otherwise healthy, except for frequent upper respiratory tract infections. His parents are not close relatives. Physical examination revealed multiple, asymptomatic, dull-coloured and irregular-shaped infiltrated erythematous plaques with a dry surface located on the trunk and limbs, and ulcerating erythemas or plaques with scab on his extremities (Fig. 1). Other physical examination was notable for mild hepatomegaly.

Blood counts demonstrated lymphopaenia (1,008 cells/mm<sup>3</sup>). IgA level (0.06 g/l) was decreased significantly. A significant reduction in T and B lymphocytes was revealed by flow cytometry analysis (Table I). Routine laboratory tests, such as ANA, anti-dsDNA antibody, ENA and T-SPOT tests, were all normal. Epstein-Barr virus DNA was not detected in plasma. Bone marrow biopsy investigation was normal. A biopsy from the plantar skin showed hyperkeratosis and focal infiltration of lymphocytes with minimal atypia in the upper and middle dermis (Fig. S1<sup>1</sup>).

**Table I. Lymphocyte subsets of the patient**

Items	Patient	Normal range
CD3+, %	25	55–82
CD3+CD4+, %	16	27–57
CD3–CD19+, %	4	10–29
CD3–CD56+, %	60	10–40

These cells were stained positively by CD4, CD5, CD20, CD56, CD68, CD79a, TIA-1 and GrB, but were negative for CD8, CD30 and CD31. The fraction of Ki-67 positive cells was 40%. The pathological diagnosis was lymphoproliferative disease (LPD).

To investigate the genetic mutations in *RAG1*, we amplified DNA extracted from whole blood of the patient and family members who provided informed consent. Direct sequencing of the *RAG1* amplification product identified novel compound heterozygous mutations in *RAG1*. Five heterozygous mutations were found at the cDNA positions of 813(c.813T>A), 870(c.870G>A), 2219(c.2219C>T), 2583(c.2583A>G) and 6440(c.6440G>A) in the patient. The patient's father has 3 heterozygous mutations at cDNA positions, including 813(c.813T>A), 870(c.870G>A) and 6440(c.6440G>A) located in the *RAG1*. Sequence analysis also showed that the *RAG1* of the patient's mother was heterozygous for 2219(c.2219C>T) mutation and homozygous for 2583(c.2583A>G) and 6440(c.6440G>A) mutations. The *RAG1* of the patient's uterine sister was homozygous for 2583(c.2583A>G) and 6440(c.6440G>A) mutations (Fig. S2<sup>1</sup>).

The patient was treated with a combination of prednisone and methotrexate and is preparing for hematopoietic stem cell transplant.

### DISCUSSION

Primary immunodeficiency disease (PID) is a group of clinical syndromes characterized by the deficiency of immune organs, immune cells or immune reactive molecules caused by gene mutations. According to the update

<sup>1</sup><https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3042>



**Fig. 1. Clinical pictures of the patient with severe combined immunodeficiency.** (a, b) Dull-coloured, irregular-shaped infiltrated erythematous plaques located on the patient's limbs. (c) Ulcers with scab on the patient's feet.

on the classification from the International Union of Immunological Societies Expert Committee in 2015, PID is divided into 9 categories, as follows: immunodeficiencies affecting cellular and humoral immunity; combined immunodeficiencies with associated or syndromic features; predominant antibody deficiencies; diseases of immune dysregulation; congenital defects of phagocyte number, function or both; defects in intrinsic and innate immunity; autoinflammatory disorders; complement deficiencies; and phenocopies of PID (5).

Compared with other PIDs, SCID is relatively common, with morbidity of 1/58,000–1/100,000 in children (6). Patients with SCID experience both severe defects in cellular immunity and humoral immunity. The pathogenesis of SCID is complicated, and a substantial majority of SCID are related to defect in the membrane and intracellular proteins. SCID is characterized by the development of the disorder. In rare cases, the dysfunction of T, B and natural killer cells is involved. On the basis of defective lymphocyte subsets, SCID can be divided into 4 groups, namely T-B+NK+, T-B+NK-, T-B-NK+ and T-B-NK-. SCID can be caused by various defects or abnormalities of genes, such as *IL2RG* (19%), *RAG1* (15%), *IL7R* (12%) and *ADA* (11%) (7).

The cutaneous symptoms of SCID mainly include eczematous lesions, erythroderma, non-infectious granuloma, microbial manifestations and LPD (8). LPD is present in more than 60 kinds of PID and commonly present in SCID, ataxia telangiectasia, Wiskott–Aldrich syndrome, X-linked lymphadenopathy, and Nijmegen breakage syndrome (9). LPD associated with PIDs may be expressed as reactive hyperplasia, pleomorphic lymphocytic hyperplasia or lymphomas (10). Slatter et al. (11) have described 2 cases of X-SCID manifested as LPD, which had CD20+ B lymphocyte infiltration.

*RAGs* are located with the human chromosome 11p13 and consist of 2 adjacent genes, that is *RAG1* and *RAG2*. DNA recombinant activating enzymes of *RAG1* and *RAG2* function are complex (12). Mutations in *RAG1* cause primary immunodeficiency, including SCID, OS, and SIgA (4, 13). *RAG1* mutation is the most common genetic defect leading to T-B-NK+ phenotype SCID, and the inheritance mode of SCID is autosomal recessive (1). Heterozygous compound mutations of *RAG1* can also lead to PID. Sharapova et al. (14) presented a 14-year-old male with SCID caused by heterozygous compound mutations, i.e. c.256-257del and c.C1331T, in *RAG1*. Matthews et al. (15) reported a boy with OS bearing compound heterozygous mutations of *RAG1*.

We report here a case of SCID with LPD as the main clinical manifestation caused by the mutations of *RAG1*. His half-blooded sister has only 2 homozygous mutations including 2583(c.2583A>G) and 6440(c.6440G>A) mutations in the *RAG1* and is healthy without SCID. We suppose that these 2 homozygous mutations do not cause SCID. His father has heterozygous mutations in 813(c.813T>AT) and 870(c.870G>AG) in *RAG1* without SCID which suggests that these 2 mutations alone may not lead to SCID. Two possibilities can be attributed to

this result; one is that the mutations of 813(c.813T>AT) and 6440(c.6440G>AG) together may cause SCID, and the other is that the mutations of 870(c.870G>AG) and 6440(c.6440G>AG) together may cause SCID.

To our knowledge, this work is the first SCID case with cutaneous LPD caused by novel compound heterozygous mutations in *RAG1*.

## ACKNOWLEDGEMENT

Funded by CAMS Innovation Fund for Medical Sciences(CIFMS-2017-I2M-1-017) and PUMC Youth Fund(3332017168)

## REFERENCES

- Buelow B J, Routes J M, Verbsky J W. Newborn screening for SCID: where are we now? *J Expert Rev Clin Immunol* 2014; 10: 1649–1657.
- Rivera-Munoz P, Malivert L, Derdouch S, Azerrad C, Abramowski V, Revy P, et al. DNA repair and the immune system: From V(D)J recombination to aging lymphocytes. *Eur J Immunol* 2007; 37: S71–S82.
- Schwarz K, Gauss G H, Ludwig L, Pannicke U, Li Z, Lindner D, et al. RAG mutations in human B cell-negative SCID. *J Science* 1996; 274: 97–99.
- Kato T, Crestani E, Kamae C, Honma K, Yokosuka T, Ikegawa T, et al. RAG1 deficiency may present clinically as selective IgA deficiency. *J Clin Immunol* 2015; 35: 280–288.
- Picard C, Alherz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. *J Clin Immunol* 2015; 35: 696–726.
- Cirillo E, Giardino G, Gallo V, D'Assante R, Grasso F, Romano R, et al. Severe combined immunodeficiency – an update. *J Annals NY Acad Sci* 2016; 1356: 90–106.
- Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. *JAMA* 2014; 312: 729–738.
- Sillevis Smitt J H, Kuijpers T W. Cutaneous manifestations of primary immunodeficiency. *J Curr Opin Pediatr* 2013; 25: 492–497.
- Chadburn A. Immunodeficiency-associated lymphoid proliferations (ALPS, HIV, and KSHV/HHV8). *J Semin Diagn Pathol* 2013; 30: 113–129.
- Gratzinger D, Jaffe ES, Chadburn A, Chan JK, de Jong D, Goodlad JR, et al. Primary/Congenital Immunodeficiency: 2015 SH/EAHP Workshop Report – Part 5. *Am J Clin Pathol* 2017; 147: 204–216.
- Slatter MA, Angus B, Windebank K, Taylor A, Meaney C, Lester T, et al. Polymorphous lymphoproliferative disorder with Hodgkin-like features in common gamma-chain-deficient severe combined immunodeficiency. *J Allergy Clin Immunol* 2011; 127: 533–535.
- Teng G, Schatz D G. Regulation and evolution of the RAG recombinase. *J Adv Immunol* 2015; 128: 1–39.
- Dalal I, Tasher D, Somech R, Etzioni A, Garti BZ, Lev D, et al. Novel mutations in RAG1/2 and ADA genes in Israeli patients presenting with T-B-SCID or Omenn syndrome. *J Clin Immunol* 2011; 140: 284–290.
- Sharapova SO, Migas A, Guryanova I, Aleshkevich S, Kletski S, Durandy A, et al. Late-onset combined immune deficiency associated to skin granuloma due to heterozygous compound mutations in RAG1 gene in a 14 years old male. *J Hum Immunol* 2013; 74: 18–22.
- Matthews AG, Briggs CE, Yamanaka K, Small TN, Mooster JL, Bonilla FA, Oettinger MA, et al. Compound heterozygous mutation of RAG1 leading to Omenn syndrome. *J PLoS One* 2015; 10: e0121489.